Obesity drug developer BioAge Labs targets up to $640 million valuation in upsized US IPO By Reuters
- Posted on September 25, 2024
- By Investing.com
- 3 Views
Obesity drug developer BioAge Labs targets up to $640 million valuation in upsized US IPO By Reuters
Obesity drug developer BioAge Labs targets up to $640 million valuation in upsized US IPO
